Dan Leonard
Stock Analyst at UBS
(3.67)
# 654
Out of 5,182 analysts
296
Total ratings
50.56%
Success rate
6.49%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHR Danaher | Maintains: Buy | $270 → $250 | $178.98 | +39.68% | 19 | Apr 22, 2026 | |
| A Agilent Technologies | Maintains: Buy | $180 → $165 | $114.87 | +43.64% | 24 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Buy | $200 → $195 | $117.43 | +66.06% | 2 | Feb 25, 2026 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $170 → $175 | $166.79 | +4.92% | 7 | Feb 25, 2026 | |
| TXG 10x Genomics | Maintains: Neutral | $14 → $20 | $21.37 | -6.41% | 8 | Feb 20, 2026 | |
| WAT Waters | Maintains: Neutral | $395 → $370 | $300.73 | +23.03% | 13 | Feb 10, 2026 | |
| IQV IQVIA Holdings | Maintains: Buy | $280 → $240 | $158.98 | +50.96% | 19 | Feb 6, 2026 | |
| TECH Bio-Techne | Maintains: Buy | $70 → $79 | $53.51 | +47.64% | 13 | Feb 5, 2026 | |
| BRKR Bruker | Maintains: Neutral | $40 → $43 | $36.26 | +18.59% | 12 | Nov 4, 2025 | |
| GH Guardant Health | Maintains: Buy | $80 → $110 | $83.09 | +32.39% | 11 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $500 → $590 | $470.22 | +25.47% | 18 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $6.14 | +144.30% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $300 → $305 | $409.65 | -25.55% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1,530 → $1,350 | $1,262.48 | +6.93% | 9 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $279.34 | +10.98% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $282.40 | +9.77% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $115 | $85.18 | +35.01% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $103.76 | -4.59% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $7.86 | +218.07% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $10.10 | -10.89% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $15.30 | +128.76% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $126.92 | +57.58% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $3.56 | +209.42% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $200.17 | -65.03% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $14.04 | -50.14% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $102.49 | +153.68% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $195.05 | -25.66% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $59 → $61 | $34.02 | +78.19% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $259.57 | +30.99% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $16.21 | +48.06% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $4.84 | +623.14% | 12 | Aug 14, 2019 |
Danaher
Apr 22, 2026
Maintains: Buy
Price Target: $270 → $250
Current: $178.98
Upside: +39.68%
Agilent Technologies
Feb 26, 2026
Maintains: Buy
Price Target: $180 → $165
Current: $114.87
Upside: +43.64%
Repligen
Feb 25, 2026
Maintains: Buy
Price Target: $200 → $195
Current: $117.43
Upside: +66.06%
Charles River Laboratories International
Feb 25, 2026
Maintains: Neutral
Price Target: $170 → $175
Current: $166.79
Upside: +4.92%
10x Genomics
Feb 20, 2026
Maintains: Neutral
Price Target: $14 → $20
Current: $21.37
Upside: -6.41%
Waters
Feb 10, 2026
Maintains: Neutral
Price Target: $395 → $370
Current: $300.73
Upside: +23.03%
IQVIA Holdings
Feb 6, 2026
Maintains: Buy
Price Target: $280 → $240
Current: $158.98
Upside: +50.96%
Bio-Techne
Feb 5, 2026
Maintains: Buy
Price Target: $70 → $79
Current: $53.51
Upside: +47.64%
Bruker
Nov 4, 2025
Maintains: Neutral
Price Target: $40 → $43
Current: $36.26
Upside: +18.59%
Guardant Health
Oct 30, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $83.09
Upside: +32.39%
Oct 23, 2025
Maintains: Neutral
Price Target: $500 → $590
Current: $470.22
Upside: +25.47%
Aug 7, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $6.14
Upside: +144.30%
Jul 29, 2025
Downgrades: Sell
Price Target: $300 → $305
Current: $409.65
Upside: -25.55%
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,262.48
Upside: +6.93%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $279.34
Upside: +10.98%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $282.40
Upside: +9.77%
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $85.18
Upside: +35.01%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $103.76
Upside: -4.59%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $7.86
Upside: +218.07%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $10.10
Upside: -10.89%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $15.30
Upside: +128.76%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $126.92
Upside: +57.58%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $3.56
Upside: +209.42%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $200.17
Upside: -65.03%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $14.04
Upside: -50.14%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $102.49
Upside: +153.68%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $195.05
Upside: -25.66%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $59 → $61
Current: $34.02
Upside: +78.19%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $259.57
Upside: +30.99%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $16.21
Upside: +48.06%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $4.84
Upside: +623.14%